BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37958914)

  • 1. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
    Robinson P; Coveñas R; Muñoz M
    Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
    Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
    Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the research and application of neurokinin-1 receptor antagonists.
    Hong X; Ma J; Zheng S; Zhao G; Fu C
    J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
    Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
    Muñoz M; Rosso M; Coveñas R
    Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
    Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
    Muñoz M; Coveñas R
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK-1 receptor antagonists: a new generation of anticancer drugs.
    Munoz M; Covenas R
    Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma.
    Yang Y; Cao X; Wang Y; Wu X; Zhou P; Miao L; Deng X
    Liver Int; 2024 Jul; 44(7):1651-1667. PubMed ID: 38554043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer progression and substance P.
    Coveñas R; Muñoz M
    Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
    Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
    Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Muñoz M; Rosso M
    Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
    Muñoz M; Coveñas R
    Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.